Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 7/2019

Open Access 01-07-2019 | Pharmacodynamics | Review Article

Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab

Authors: Kioa Lente Wijnsma, Rob ter Heine, Dirk Jan A. R. Moes, Saskia Langemeijer, Saskia E. M. Schols, Elena. B. Volokhina, Lambertus P. van den Heuvel, Jack F. M. Wetzels, Nicole C. A. J. van de Kar, Roger J. Brüggemann

Published in: Clinical Pharmacokinetics | Issue 7/2019

Login to get access

Abstract

Eculizumab is the first drug approved for the treatment of complement-mediated diseases, and current dosage schedules result in large interindividual drug concentrations. This review provides insight into the pharmacokinetic and pharmacodynamic properties of eculizumab, both for reported on-label (paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis) and off-label (hematopoietic stem cell transplantation-associated thrombotic microangiopathy) indications. Furthermore, we discuss the potential of therapeutic drug monitoring to individualize treatment and reduce costs.
Literature
1.
Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233–43.PubMed
2.
Hillmen P, Hall C, Marsh JCW, Elebute M, Bombara MP, Petro BE, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350(6):552–9.PubMed
3.
US Food and Drug Administration (FDA). Clinical pharmacology and biopharmaceutics review. Silver Spring: US FDA; 2007.
4.
Ricklin D, Mastellos DC, Reis ES, Lambris JD. The renaissance of complement therapeutics. Nat Rev Nephrol. 2018;14(1):26–47.PubMed
5.
European Medicines Ageny (EMA). CHMP extension of indication variation assessment report. London: EMA; 2017.
6.
Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169–81.PubMed
7.
Castaneda-Sanabria J, Hajage D, Le Jouan M, Perozziello A, Tubach F. Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field. Eur J Clin Pharmacol. 2016;72(6):737–46.PubMed
8.
Coyle D, Cheung MC, Evans GA. Opportunity cost of funding drugs for rare diseases: the cost-effectiveness of eculizumab in paroxysmal nocturnal hemoglobinuria. Med Decis Mak. 2014;34(8):1016–29.
9.
Gatault P, Brachet G, Ternant D, Degenne D, Recipon G, Barbet C, et al. Therapeutic drug monitoring of eculizumab: rationale for an individualized dosing schedule. MAbs. 2015;7(6):1205–11.PubMedPubMedCentral
10.
Volokhina E, Wijnsma K, van der Molen R, Roeleveld N, van der Velden T, Goertz J, et al. Eculizumab dosing regimen in atypical HUS: Possibilities for individualized treatment. Clin Pharmacol Ther. 2017;102(4):671–8.PubMed
11.
Alashkar F, Vance C, Herich-Terhurne D, Preising N, Duhrsen U, Roth A. Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab. Ann Hematol. 2017;96(4):589–96.PubMed
12.
Hayes W, Tschumi S, Ling SC, Feber J, Kirschfink M, Licht C. Eculizumab hepatotoxicity in pediatric aHUS. Pediatr Nephrol. 2015;30(5):775–81.PubMed
13.
Oruc A, Ayar Y, Vuruskan BA, Yildiz A, Aktas N, Yavuz M, et al. Hepatotoxicity associated with eculizumab in a patient with atypical hemolytic uremic syndrome. Nefrologia. 2018;38(4):448–50.PubMed
14.
Liszewski MK, Java A, Schramm EC, Atkinson JP. Complement dysregulation and disease: insights from contemporary genetics. Annu Rev Pathol. 2017;12:25–52.PubMed
15.
16.
Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111(4):1840–7.PubMed
17.
European Medicines Ageny (EMA). Summary of product characteristcs. London: EMA; 2017.
18.
Jodele S, Fukuda T, Mizuno K, Vinks AA, Laskin BL, Goebel J, et al. Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(2):307–15.PubMed
19.
Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fremeaux-Bacchi V. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8(11):643–57.PubMed
20.
Le Quintrec M, Lionet A, Kandel C, Bourdon F, Gnemmi V, Colombat M, et al. Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Am J Kidney Dis. 2015;65(3):484–9.PubMed
21.
Barbour TD, Ruseva MM, Pickering MC. Update on C3 glomerulopathy. Nephrol Dial Transplant. 2016;31(5):717–25.PubMed
22.
Oosterveld MJ, Garrelfs MR, Hoppe B, Florquin S, Roelofs JJ, van den Heuvel LP, et al. Eculizumab in pediatric dense deposit disease. Clin J Am Soc Nephrol. 2015;10(10):1773–82.PubMedPubMedCentral
23.
Sciascia S, Radin M, Yazdany J, Tektonidou M, Cecchi I, Roccatello D, et al. Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Rheumatol Int. 2017;37(8):1249–55.PubMed
24.
Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fremeaux-Bacchi V, Kavanagh D, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “kidney disease: improving global outcomes” (KDIGO) Controversies Conference. Kidney Int. 2017;91(3):539–51.PubMed
25.
Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J, et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant. 2014;20(4):518–25.PubMed
26.
Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol. 2012;7(5):748–56.PubMedPubMedCentral
27.
Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment of dense-deposit disease. N Engl J Med. 2012;366(12):1163–5.PubMed
28.
De Amorim Garcia Filho CA, Yehoshua Z, Gregori G, Nunes RP, Penha FM, Moshfeghi AA, et al. Change in Drusen volume as a novel clinical trial endpoint for the study of complement inhibition in age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2014;45(1):18–31.
29.
Delmas Y, Vendrely B, Clouzeau B, Bachir H, Bui HN, Lacraz A, et al. Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol Dial Transplant. 2014;29(3):565–72.PubMed
30.
De Fontbrune FS, Galambrun C, Sirvent A, Huynh A, Faguer S, Nguyen S, et al. Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC. Transplantation. 2015;99(9):1953–9.PubMed
31.
Griffin M, Munir T. Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician’s guide. Ther Adv Hematol. 2017;8(3):119–26.PubMed
32.
Hillmen P, Elebute M, Kelly R, Urbano-Ispizua A, Hill A, Rother RP, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2010;85(8):553–9.PubMed
33.
Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship TH, et al. Atypical aHUS: state of the art. Mol Immunol. 2015;67(1):31–42.PubMed
34.
Fakhouri F, Zuber J, Fremeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;390(10095):681–96.PubMed
35.
Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome. Semin Immunopathol. 2014;36(4):399–420.PubMed
36.
Howard JF Jr, Barohn RJ, Cutter GR, Freimer M, Juel VC, Mozaffar T, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013;48(1):76–84.PubMed
37.
Schubert J, Menne J. Eculizumab for the treatment of hemolytic paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and refractory myasthenia gravis. Expert Opin Orphan Drugs. 2017;5(4):375–9.
38.
39.
Howard JF Jr. Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci. 2018;1412(1):113–28.PubMed
40.
Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J, et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood. 2014;124(4):645–53.PubMedPubMedCentral
41.
European Medicines Agency (EMA). Assessment report eculizumab. London: EMA; 2013.
42.
European Medicines Agency (EMA). Soliris: EPAR—scientific discussion. London: EMA; 2007.
43.
Furie R, Matis L, Rollins S, et al. A single dose, placebo-controlled, double blind, phase I study of the humanized anti-C5 antibody hbG1.1 in patients with systemic lupus erythematosus. Abstract presented at the 64th annual scientific meeting of the American College of Rheumatology, Philadelphia, PA.
44.
Jain RI, Moreland LW, Caldwell JR, Rollins SA, Mojcik CF. A single dose, placebo controlled, double blind, phase I study of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis. Arthritis Rheum. 1999;42:S77.
45.
Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013;12(6):554–62.PubMed
46.
Takada K, Bookbinders S, Furie R. A pilot study of eculizumab in patients with dermatomyositis. Arthritis Rheum. 2002;46(S489).
47.
Schubert J, Hillmen P, Roth A, Young NS, Elebute MO, Szer J, et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2008;142(2):263–72.PubMedPubMedCentral
48.
Yelken B, Arpali E, Gorcin S, Kocak B, Karatas C, Demiralp E, et al. Eculizumab for treatment of refractory antibody-mediated rejection in kidney transplant patients: a single-center experience. Transplant Proc. 2015;47(6):1754–9.PubMed
49.
Sheridan D, Yu ZX, Zhang Y, Patel R, Sun F, Lasaro MA, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PloS one. 2018;13(4):e0195909.PubMedPubMedCentral
50.
Keizer RJ, Huitema ADR, Schellens JHM, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493–507.PubMed
51.
Dmytrijuk A, Robie-Suh K, Cohen MH, Rieves D, Weiss K, Pazdur R. FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist. 2008;13(9):993–1000.PubMed
52.
Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, et al. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol. 2017;187(2):304–15.PubMed
53.
Volokhina EB, van de Kar NC, Bergseth G, van der Velden TJ, Westra D, Wetzels JF, et al. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clin Immunol. 2015;160(2):237–43.PubMed
54.
Yuan D, Rode F, Cao Y. A minimal physiologically based pharmacokinetic model with a nested endosome compartment for novel engineered antibodies. AAPS J. 2018;20(3):48.PubMed
55.
De Latour RP, Fremeaux-Bacchi V, Porcher R, Xhaard A, Rosain J, Castaneda DC, et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood. 2015;125(5):775–83.
56.
US Food and Drug Administration (FDA). Approval package aHUS. US FDA: Silver Spring; 2011.
57.
Hillmen P, Muus P, Roth A, Elebute MO, Risitano AM, Schrezenmeier H, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162(1):62–73.PubMedPubMedCentral
58.
US Food and Drug Administration (FDA). Prescribing information. Silver Spring: US FDA; 2017.
59.
Reiss UM, Schwartz J, Sakamoto KM, Puthenveetil G, Ogawa M, Bedrosian CL, et al. Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria. Pediatr Blood Cancer. 2014;61(9):1544–50.PubMed
60.
Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016;89(3):701–11.PubMed
61.
European Medicines Agency (EMA). CHMP variation assessment report Type II variation. EMEA/H/C/000791/II/0027. London: EMA; 2011.
62.
Fitzpatrick AM, Mann CA, Barry S, Brennan K, Overell JR, Willison HJ. An open label clinical trial of complement inhibition in multifocal motor neuropathy. J Peripher Nerv Syst. 2011;16(2):84–91.PubMed
63.
Hillmen P, Muus P, Szer J, Hill A, Hochsmann B, Kulasekararaj A, et al. Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2016;91(3):E16–7.PubMed
64.
Vekemans MC, Lambert C, Ferrant A, Saussoy P, Havelange V, Debieve F, et al. Management of pregnancy in paroxysmal nocturnal hemoglobinuria on long-term eculizumab. Blood Coagul Fibrinol. 2015;26(4):464–6.
65.
Sharma R, Keyzner A, Liu J, Bradley T, Allen SL. Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis. Leuk Res Rep. 2015;4(1):36–8.PubMedPubMedCentral
66.
Gately R, San A, Kurtkoti J, Parnham A. Life-threatening pregnancy-associated atypical haemolytic uraemic syndrome and its response to eculizumab. Nephrology (Carlton). 2017;22(Suppl 1):32–5.PubMed
67.
Ardissino G, Ossola MW, Baffero GM, Rigotti A, Cugno M. Eculizumab for atypical hemolytic uremic syndrome in pregnancy. Obstet Gynecol. 2013;122(2 Part 2):487–9.PubMed
68.
Kelly R, Arnold L, Richards S, Hill A, Bomken C, Hanley J, et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol. 2010;149(3):446–50.PubMed
69.
Servais A, Devillard N, Fremeaux-Bacchi V, Hummel A, Salomon L, Contin-Bordes C, et al. Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab. Nephrol Dial Transplant. 2016;31(12):2122–30.PubMed
70.
Kelly RJ, Hochsmann B, Szer J, Kulasekararaj A, de Guibert S, Roth A, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2015;373(11):1032–9.PubMed
71.
Willrich MAV, Andreguetto BD, Sridharan M, Fervenza FC, Tostrud LJ, Ladwig PM, et al. The impact of eculizumab on routine complement assays. J Immunol Methods. 2018;460:63–71.PubMed
72.
Puissant-Lubrano B, Puissochet S, Congy-Jolivet N, Chauveau D, Decramer S, Garnier A, et al. Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab. Clin Immunol. 2017;183:1–7.PubMed
73.
US Food and Drug Administration (FDA). Pharmacometrics review. Silver Spring: US FDA; 2007.
74.
Hill A, Rother RP, Wang X, Morris SM Jr, Quinn-Senger K, Kelly R, et al. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2010;149(3):414–25.PubMed
75.
Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87(5):1061–73.PubMedPubMedCentral
76.
Harder MJ, Kuhn N, Schrezenmeier H, Hochsmann B, Von Zabern I, Weinstock C, et al. Incomplete inhibition by eculizumab: Mechanistic evidence for residual C5 activity during strong complement activation. Blood. 2017;129(8):970–80.PubMedPubMedCentral
77.
Sica M, Rondelli T, Ricci P, De Angioletti M, Risitano AM, Notaro R. Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes. J Hematol Oncol. 2017;10(1):126.PubMedPubMedCentral
78.
Nishimura JI, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014;370(7):632–9.PubMed
79.
Du Y, Zhang Q, Han B. Genetic variants of C5 and polymorphisms of C3 in Chinese patients with paroxysmal nocturnal hemoglobinuria. Int J Lab Hematol. 2016;38(4):e84–5.PubMed
80.
Schatz-Jakobsen JA, Zhang Y, Johnson K, Neill A, Sheridan D, Andersen GR. Structural basis for eculizumab-mediated inhibition of the complement terminal pathway. J Immunol. 2016;197(1):337–44.PubMed
81.
82.
Ardissino G, Possenti I, Tel F, Testa S, Salardi S, Ladisa V. Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update. Am J Kidney Dis. 2015;66(1):172–3.PubMed
83.
Ardissino G, Tel F, Sgarbanti M, Cresseri D, Giussani A, Griffini S, et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update. Pediatr Nephrol. 2018;33(3):457–61.PubMed
84.
85.
86.
Mallett A, Hughes P, Szer J, Tuckfield A, Van Eps C, Cambell SB, et al. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort. Intern Med J. 2015;45(10):1054–65.PubMed
87.
88.
Gediz F, Payzin BK, Ecemis S, Guler N, Yilmaz AF, Topcugil F, et al. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey. Transfus Apher Sci. 2016;55(3):357–62.PubMed
89.
Ito N, Hataya H, Saida K, Amano Y, Hidaka Y, Motoyoshi Y, et al. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol. 2016;20(2):265–72.PubMed
90.
Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol. 2017;30(1):127–34.PubMed
91.
Cugno M, Tedeschi S, Ardissino G. Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis: comment. J Thromb Haemost. 2015;13(3):485–6.PubMed
92.
Wehling C, Kirschfink M. Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis. J Thromb Haemost. 2014;12(9):1437–9.PubMed
93.
Hillmen P, Muus P, Duhrsen U, Risitano AM, Schubert J, Luzzatto L, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110(12):4123–8.PubMed
94.
Hill A, Hillmen P, Richards SJ, Elebute D, Marsh JC, Chan J, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood. 2005;106(7):2559–65.PubMed
95.
Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: Sustained efficacy and improved survival. Blood. 2011;117(25):6786–92.PubMed
96.
Roth A, Hock C, Konik A, Christoph S, Duhrsen U. Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: Safety, efficacy, and unexpected laboratory phenomena. Int J Hematol. 2011;93(6):704–14.PubMed
97.
Ninomiya H, Obara N, Chiba S, Usuki K, Nishiwaki K, Matsumura I, et al. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol. 2016;104(5):548–58.PubMed
98.
US Food and Drug Administration (FDA). Pharmacology and toxicology review and evaluation. Silver Spring: US FDA; 2006.
99.
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976–86.PubMed
100.
Kielstein JT, Beutel G, Fleig S, Steinhoff J, Meyer TN, Hafer C, et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant. 2012;27(10):3807–15.PubMed
101.
Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant. 2011;11(11):2405–13.PubMed
102.
Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, Gregori G, Penha FM, Moshfeghi AA, et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. Ophthalmology. 2014;121(3):693–701.PubMed
103.
Davidson AI, Halstead SK, Goodfellow JA, Chavada G, Mallik A, Overell J, et al. Inhibition of complement in Guillain-Barre syndrome: the ICA-GBS study. J Peripher Nerv Syst. 2017;22(1):4–12.PubMed
104.
Mevorach D, Reiner I, Grau A, Ilan U, Berkun Y, Ta-Shma A, et al. Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation. Ann Neurol. 2016;80(5):708–17.PubMed
Metadata
Title
Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
Authors
Kioa Lente Wijnsma
Rob ter Heine
Dirk Jan A. R. Moes
Saskia Langemeijer
Saskia E. M. Schols
Elena. B. Volokhina
Lambertus P. van den Heuvel
Jack F. M. Wetzels
Nicole C. A. J. van de Kar
Roger J. Brüggemann
Publication date
01-07-2019
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 7/2019
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-019-00742-8

Other articles of this Issue 7/2019

Clinical Pharmacokinetics 7/2019 Go to the issue

Letter to the Editor

Comment on “Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?”

Letter to the Editor

Authors’ Reply to Coste et al.: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”

Original Research Article

The Population Pharmacokinetics of High-Dose Methotrexate in Infants with Acute Lymphoblastic Leukemia Highlight the Need for Bedside Individualized Dose Adjustment: A Report from the Children’s Oncology Group

Review Article

Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors

Letter to the Editor

Comment on: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”

Current Opinion

Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?